TABLE 1.
Active U.S. Trials of PARP Inhibitors (Breast Cancer Eligible)
| Agents | Phase | Combination Agent |
ClinicalTrials.Gov Number |
|---|---|---|---|
| BSI-201 | 3 | Gemcitabine/carboplatin | NCT00938652 |
| 2 (neoadjuvant) | Gemcitabine/carboplatin | NCT00813956 | |
| 1 | Irinotecan | NCT00298675 | |
| 1 | Various | NCT00422082 | |
| Olaparib (AZD2281) | 1 | Carboplatin | NCT00647062 |
| 1 | Gemcitabine/cisplatin | NCT00678132 | |
| ABT888 | 1 | Single agent | NCT00810966 |
| NCT00892736 | |||
| 1 | Cyclophosphamide ± doxorubicin | NCT00740805 | |
| 1 | Paclitaxel/carboplatin | NCT00535119 | |
| 1 | Topotecan | NCT00553189 | |
| MK-4827 | 1 | Single | NCT00749502 |
| AG014699 (no active U.S. studies) | |||
| INO1001 (no active U.S. studies) |